PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring PIK3CA Mutations

PURPOSE: Mutations of the PIK3CA gene may predict response to phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) inhibitors. Concomitant mutations in the mitogen-activated protein kinase (MAPK) pathway may mediate resistance. PATIENTS AND METHODS: Tumors from patients with...

詳細記述

保存先:
書誌詳細
主要な著者: Janku, Filip, Wheler, Jennifer J., Westin, Shannon N., Moulder, Stacy L., Naing, Aung, Tsimberidou, Apostolia M., Fu, Siqing, Falchook, Gerald S., Hong, David S., Garrido-Laguna, Ignacio, Luthra, Rajyalakshmi, Lee, J. Jack, Lu, Karen H., Kurzrock, Razelle
フォーマット: Artigo
言語:Inglês
出版事項: American Society of Clinical Oncology 2012
主題:
Original Reports
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3295566/
https://ncbi.nlm.nih.gov/pubmed/22271473
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.36.1196
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料